Matches in SemOpenAlex for { <https://semopenalex.org/work/W2927231191> ?p ?o ?g. }
- W2927231191 endingPage "417" @default.
- W2927231191 startingPage "396" @default.
- W2927231191 abstract "Abstract Uveitis is a spectrum of inflammatory disorders characterized by ocular inflammation and is one of the leading causes of preventable visual loss. The main aim of the treatment of uveitis is to control the inflammation, prevent recurrences of the disease and preserve vision while minimizing the adverse effects associated with the therapeutic agents. Initial management of uveitis relies heavily on the use of corticosteroids. However, monotherapy with high‐dose corticosteroids is associated with side effects and cannot be maintained long term. Therefore, steroid‐sparing agents are needed to decrease the burden of steroid therapy. Currently, the therapeutic approach for non‐infectious uveitis (NIU) consists of a step‐ladder strategy with the first‐line option being corticosteroids in various formulations followed by the use of first‐, second‐ and third‐line agents in cases with suboptimal steroid response. Unfortunately, the agents currently at our disposal have limitations such as having a narrow therapeutic window along with their own individual potential side‐effect profiles. Therefore, research has been targeted to identify newer drugs as well as new uses for older drugs that target specific pathways in the inflammatory response. Such efforts are made in order to provide targeted and safer therapy with reduced side effects and greater efficacy. Several specially designed molecular antibodies are currently in various phases of investigations that can potentially halt the inflammation in patients with NIU. In the review, we have provided a comprehensive overview of the current and upcoming therapeutic options for patients with NIU." @default.
- W2927231191 created "2019-04-11" @default.
- W2927231191 creator A5007575811 @default.
- W2927231191 creator A5010289666 @default.
- W2927231191 creator A5028692320 @default.
- W2927231191 creator A5030842636 @default.
- W2927231191 creator A5049843773 @default.
- W2927231191 creator A5059309292 @default.
- W2927231191 creator A5064695755 @default.
- W2927231191 creator A5067253160 @default.
- W2927231191 creator A5079655489 @default.
- W2927231191 creator A5080631815 @default.
- W2927231191 creator A5091022089 @default.
- W2927231191 date "2019-04-01" @default.
- W2927231191 modified "2023-09-25" @default.
- W2927231191 title "New therapies in development for the management of non‐infectious uveitis: A review" @default.
- W2927231191 cites W1255501339 @default.
- W2927231191 cites W142084292 @default.
- W2927231191 cites W1490753351 @default.
- W2927231191 cites W1499673414 @default.
- W2927231191 cites W1524785835 @default.
- W2927231191 cites W1566770361 @default.
- W2927231191 cites W1635512559 @default.
- W2927231191 cites W1719749797 @default.
- W2927231191 cites W172362473 @default.
- W2927231191 cites W1803398899 @default.
- W2927231191 cites W1866549238 @default.
- W2927231191 cites W1915798083 @default.
- W2927231191 cites W1931337664 @default.
- W2927231191 cites W1965014085 @default.
- W2927231191 cites W1965340632 @default.
- W2927231191 cites W1965766554 @default.
- W2927231191 cites W1968434914 @default.
- W2927231191 cites W1968779223 @default.
- W2927231191 cites W1972017473 @default.
- W2927231191 cites W1973387000 @default.
- W2927231191 cites W1974798515 @default.
- W2927231191 cites W1974947034 @default.
- W2927231191 cites W1975525636 @default.
- W2927231191 cites W1975837824 @default.
- W2927231191 cites W1981891070 @default.
- W2927231191 cites W1983349384 @default.
- W2927231191 cites W1984188767 @default.
- W2927231191 cites W1984873885 @default.
- W2927231191 cites W1988413772 @default.
- W2927231191 cites W1994243439 @default.
- W2927231191 cites W1995106708 @default.
- W2927231191 cites W1997010731 @default.
- W2927231191 cites W1998647493 @default.
- W2927231191 cites W1998677128 @default.
- W2927231191 cites W1999494306 @default.
- W2927231191 cites W2000183493 @default.
- W2927231191 cites W2000256194 @default.
- W2927231191 cites W2001815569 @default.
- W2927231191 cites W2002696122 @default.
- W2927231191 cites W2004469077 @default.
- W2927231191 cites W2005391764 @default.
- W2927231191 cites W2005475150 @default.
- W2927231191 cites W2008345204 @default.
- W2927231191 cites W2009923660 @default.
- W2927231191 cites W2012806608 @default.
- W2927231191 cites W2013212307 @default.
- W2927231191 cites W2013902303 @default.
- W2927231191 cites W2014788180 @default.
- W2927231191 cites W2014881502 @default.
- W2927231191 cites W2014970500 @default.
- W2927231191 cites W2015212522 @default.
- W2927231191 cites W2015619278 @default.
- W2927231191 cites W2015690288 @default.
- W2927231191 cites W2016300251 @default.
- W2927231191 cites W2017068190 @default.
- W2927231191 cites W2017575727 @default.
- W2927231191 cites W2020954282 @default.
- W2927231191 cites W2021616554 @default.
- W2927231191 cites W2022346239 @default.
- W2927231191 cites W2022850278 @default.
- W2927231191 cites W2024399038 @default.
- W2927231191 cites W2024860303 @default.
- W2927231191 cites W2026992146 @default.
- W2927231191 cites W2027090790 @default.
- W2927231191 cites W2030108904 @default.
- W2927231191 cites W2030454808 @default.
- W2927231191 cites W2030924703 @default.
- W2927231191 cites W2032140498 @default.
- W2927231191 cites W2032345888 @default.
- W2927231191 cites W2035060637 @default.
- W2927231191 cites W2035244366 @default.
- W2927231191 cites W2036919132 @default.
- W2927231191 cites W2037382237 @default.
- W2927231191 cites W2037966248 @default.
- W2927231191 cites W2038079507 @default.
- W2927231191 cites W2038535814 @default.
- W2927231191 cites W2043198160 @default.
- W2927231191 cites W2043568921 @default.
- W2927231191 cites W2043641414 @default.
- W2927231191 cites W2045210947 @default.
- W2927231191 cites W2045952946 @default.
- W2927231191 cites W2046411916 @default.